NewAmsterdam Pharma amends 8-K to disclose COO Douglas Kling separation, advisor agreement terms

Reuters2026/08/14 20:17

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

NewAmsterdam Pharma amended a July 22, 2026 Form 8-K to disclose terms of Douglas Kling’s separation and advisory arrangements.
Kling’s resignation as chief operating officer takes effect Aug. 14, 2026 to become CEO of another clinical-stage biotech company.
Unvested stock options and RSUs were forfeited, except awards eligible to vest through May 14, 2027 if he provides advisory services.
Advisor agreement pays USD 50,000 per month for transition work tied to the PREVAIL obicetrapib trial, running through May 14, 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NewAmsterdam Pharma Company NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-352233), on August 14, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

NewAmsterdam Pharma amends 8-K to disclose COO Douglas Kling separation, advisor agreement terms

You may also like

Crypto prices